// App-Quantinova.ai

: Personalized and Optimized Low-Dose and Intensive Chemotherapy Treatments for Patients with Acute Myeloid Leukemia (AML)

Researchers

Presenter

  • Ana Luz Quiroga-Campano

Principal Investigators

  • Louise Enfield

  • Matthew Foster

  • Margaritis Kostoglou

  • Michael Georgiadis

  • Athanasios Mantalaris

  • Nicki Panoskaltsis

Medical Centers

  • Biological Systems Engineering Laboratory, Department of Chemical Engineering, Imperial College London, London, United Kingdom

  • Haematology Clinical Research Unit, London North West Healthcare NHS Trust, London, United Kingdom

  • Department of Biochemistry Medical School, Aristotles University of Thessaloniki, Thessaloniki, Greece

  • Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece

  • Biological Systems Engineering Laboratory, Department of Chemical Engineering, Imperial College London, London, United Kingdom

  • Department of Histopathology, Imperial College London, London, United Kingdom

  • Biological System Engineering Laboratory, Imperial College London, London, United Kingdom

Locations

  • United Kingdom

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • White Blood Cell

  • Red Blood Cells

Drug/Treatment

  • Daunorubicin

  • Cytarabine liposomal

  • Methadone hydrochloride

  • ara-c

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved